Key result
Crocin administration (30 mg/day for 8 weeks) significantly increased serum HDL cholesterol uptake capacity compared to placebo in patients with metabolic syndrome (p<0.05).
Why the study?
High-density lipoprotein cholesterol uptake capacity is reduced in patients with metabolic syndrome, prompting assessment of the effect of crocin supplementation on this parameter.
Does crocin supplementation improve HDL cholesterol uptake capacity in patients with metabolic syndrome?
RCT (n=44)
randomly allocated
Does crocin supplementation improve HDL cholesterol uptake capacity in patients with metabolic syndrome?
p-value: p=< 0.05
Crocin supplementation at 30 mg daily for 8 weeks significantly improves HDL cholesterol uptake capacity in patients with metabolic syndrome.
Crocin may improve HDL CUC in MetS; hypothesis-generating and requires larger trials before clinical consideration.
A randomized clinical trial high-density lipoprotein (HDL) cholesterol uptake capacity (CUC) is reduced in patients with metabolic syndrome (MetS). We have assessed the effect of crocin supplementation on HDL CUC in patients with MetS. Forty-four subjects with MetS were randomly allocated to one of two groups: one group received placebo and the other group received crocin at a dose of 30 mg (two tablets of 15 mg per day) for 8 weeks. Serum biochemical parameters were measured using an AutoAnalyzer BT3000 (BioTechnica). The modified CUC method is a cell free, simple, and high-throughput assay that used to evaluate HDL CUC of serum samples. The decision tree analysis was undertaken using JMP Pro (SAS) version 13. The mean age of the crocin and placebo groups were 38.97 ± 13.33 and 43.46 ± 12.77 years, respectively. There was a significant increase in serum HDL CUC in the crocin group compared to that of the placebo group in patients with MetS (p-value< 0.05). The decision tree analysis showed that serum HDL functionality was more important variable than HDL-C level in predicting patients with hypertension at baseline (p-value < 0.05). Crocin administration (30 mg for a period of 8 weeks) was found to improve serum HDL CUC in patients with MetS. TRIAL REGISTRATION: IRCT2013080514279N1.
No takes yet. Share an insight, caveat, or question.
Saberi‐Karimian et al. (2021) conducted an RCT in metabolic syndrome (n=44). crocin vs. placebo was evaluated on serum HDL cholesterol uptake capacity (CUC) (p=< 0.05). Crocin administration (30 mg/day for 8 weeks) significantly increased serum HDL cholesterol uptake capacity compared to placebo in patients with metabolic syndrome (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: